title: Lack of effect of IGF-I on the glomerular filtration rate in non-diabetic patients with advanced chronic kidney disease.
abstract: Recombinant human insulin-like growth factor I (rhIGF-I) acutely increases the glomerular filtration rate (GFR) in human volunteers and patients with advanced chronic kidney disease (CKD). However, on chronic administration, rhIGF-I induces tolerance to its renal effects attributed to a fall in serum IGF-binding protein 3 (IGFBP-3) enhancing its systemic clearance. Tolerance may be avoided by the use of an intermittent dosage regimen of rhIGF-I. A randomised, double-blind, placebo-controlled study was undertaken in non-diabetic patients with advanced CKD to establish whether intermittent subcutaneous injections of rhIGF-I (50 microg/kg, four days/week) could increase GFR over a 24 week period and thereby have the potential to delay the onset of renal replacement therapy. Twenty-seven patients were randomised into rhIGF-I/placebo groups using a 2:1 treatment ratio. GFR was determined by inulin clearance. RhIGF-I therapy produced a sustained increase serum total and free IGF-I elevating IGFBP-1 without decreasing IGFBP-3. Inulin clearance however, was not increased after either four weeks or over the 24 week observation period. Only 4/18 rhIGF-I treated patients compared to 6/9 placebo patients completed the study, the major reason being the requirement for dialysis. Compared with healthy volunteers, advanced CKD patients had elevated serum levels of IGFBP-1, IGFBP-2, tumour necrosis factor-alpha and asymmetric dimethylarginine, all factors proposed to mediate IGF-I resistance. In conclusion, although intermittent rhIGF-I therapy elevated serum total IGF-I and prevented any fall in serum IGFBP-3, it failed to increase GFR in non-diabetic patients with advanced CKD. The lack of efficacy was attributed to the presence of renal IGF-I resistance in CKD.
authors.affiliation: Sheffield Kidney Institute, School of Medicine and Biomedical Sciences, University of Sheffield, Medical School, Sheffield, UK.
authors.forename: Ying
authors.initials: Y
authors.lastname: Kuan
authors.forename: Joanne
authors.initials: J
authors.lastname: Surman
authors.forename: Jan
authors.initials: J
authors.lastname: Frystyk
authors.forename: A Meguid
authors.initials: AM
authors.lastname: El Nahas
authors.forename: Allan
authors.initials: A
authors.lastname: Flyvbjerg
authors.forename: John L
authors.initials: JL
authors.lastname: Haylor
mesh_terms: D058186:Acute Kidney Injury / Q000188:drug therapy; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005455:Fluorescent Antibody Technique; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007279:Injections, Subcutaneous; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011994:Recombinant Proteins / Q000494:pharmacology*; D017211:Treatment Failure
chemical_list: D010919:Placebos; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I